跳至主要内容
临床试验/RPCEC00000416
RPCEC00000416已完成2 期

Efficacy and safety of the PROCTOKINASA® suppository in the treatment of acute pelvic inflammatory disease in Primary Care

Matanzas University of Medical Sciences0 个研究点目标入组 76 人开始时间: 2023年2月9日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
76

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
19 years 至 one(—)
性别
Female

入选标准

  • 1. Female patients with a clinical and ultrasound diagnosis of mild and moderate acute pelvic inflammatory disease who have signed the informed consent.
  • 2. Patients over 18 years of age.
  • 3. Patients who do not require hospitalization.

排除标准

  • 1. Patients who are participating in another clinical trial.
  • 2. Breastfeeding patients.
  • 3. Patients with a history of hypersensitivity to the product or to any of the components of the formulation.
  • 4. Female patients with a clinical and ultrasound diagnosis of severe PID or with criteria for hospitalization.
  • 5. Patients with surgery for less than 7 days, active bleeding or previously diagnosed bleeding disorder.
  • 6. Patients with a diagnosis of arterial hypertension.

研究者

发起方
Matanzas University of Medical Sciences

相似试验